drugset / Trial / NCT06744894
SIL as Maintenance Therapy in Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.
Timeline
- Start
- 2025-01-01
- Primary completion
- 2028-01-01
- Completion
- 2030-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |